Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world evaluation of agomelatine for major depressive disorder
ChiCTR2200061464Phase 4Not yet recruiting
- Sponsor
- Zhongda Hospital, Southeast University
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of agomelatine in major depressive disorder (MDD), sponsored by Zhongda Hospital, Southeast University. Primary endpoint: scores of different scales. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200061464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061464.